Despite its affinity for fibrin, tissue plasminogen activator (t-PA) administration causes systemic fibrinogenolysis. To investigate the mechanism, t-PA was incubated with plasma in the presence or absence of a fibrin clot, and the extent of fibrinogenolysis was determined by measuring B,3142. In the presence of fibrin, there is a 21-fold increase in B,O142 levels. The potentiation of fibrinogenolysis in the presence of fibrin is mediated by soluble fibrin degradation products because (a) the extent of t-PA induced fibrinogenolysis and clot lysis are directly related, (b) once clot lysis has been initiated, fibrinogenolysis continues even after the clot is removed, and (c) lysates of cross-linked fibrin clots potentiate t-PA-mediated fibrinogenolysis. Fibrin degradation products stimulate fibrinogenolysis by binding t-PA and plasminogen because -70% of the labeled material in the clot lysates binds to both t-PA-and plasminogen-Sepharose, and only the bound fractions have potentiating activity. The binding site for t-PA and plasminogen is on the E domain because characterization of the potentiating fragments using gel filtration followed by PAGE and immunoblotting indicates that the major species is (DD)E complex, whereas minor components include high-molecular weight derivatives containing the (DD)E complex and fragment E. In contrast, D-dimer is the predominant species found in the fractions that do not bind to the adsorbants, and it has no potentiating activity. Thus, soluble products of t-PA-induced lysis of cross-linked fibrin potentiate t-PA-mediated fibrinogenolysis by providing a surface for t-PA and plasminogen binding thereby promoting plasmin generation. The occurrence of this phenomenon after therapeutic thrombolysis may explain the limited clot selectivity of t-PA. (J. Clin.
Introduction
Tissue-type plasminogen activator (t-PA)' converts plasminogen to plasmin, thereby initiating fibrinolysis (1) . The property that distinguishes t-PA from urokinase, the other major endoge- nous plasminogen activator, is its relative fibrin selectivity. Both t-PA and plasminogen bind to fibrin (1) (2) (3) (4) where they undergo conformational changes (5, 6) which promote their interaction and enhance plasmin generation on the clot surface (7, 8) , where it is relatively protected from inactivation by a2-antiplasmin (1, 4) . Through this mechanism, t-PA has the potential to produce clot lysis without inducing a systemic lytic state.
The clot-selective properties of t-PA provided the major impetus for the development of t-PA as a therapeutic agent. With the successful cloning and expression of t-PA cDNA (9) , amounts of recombinant t-PA (rt-PA) sufficient for clinical studies have recently become available. Although rt-PA is an extremely effective thrombolytic agent, its use in patients with acute myocardial infarction (10) (11) (12) (13) (14) (15) and venous thromboembolic disease (16) (17) (18) (19) results in significant fibrinogen proteolysis, albeit to a lesser extent than that produced by streptokinase (12) (13) (14) (15) . Thus, large clinical studies have demonstrated that in pharmacologically effective doses, rt-PA is not fibrin-specific.
There are two potential reasons why rt-PA administration is associated with systemic fibrinogenolysis despite the in vitro evidence that t-PA is clot-specific. One is based on theoretical calculations of the reported kinetic parameters for the interaction between plasminogen and t-PA. Using computer-assisted simulation, these models predicted that thrombolytic doses of rt-PA would produce systemic fibrinogenolysis (20, 21 ). Another potential explanation for the limited clot selectivity of rt-PA is that products ofthrombolysis augment fibrinogen proteolysis. This concept is supported by the results of in vitro studies demonstrating that fibrin fragments accelerate plasminogen activation by t-PA in buffer systems (22) (23) (24) (25) (26) (27) (28) . In this investigation, we performed studies in a plasma system (a) to determine whether soluble degradation products of crosslinked fibrin can potentiate rt-PA induced fibrinogenolysis, and (b) to explore the mechanism of potentiation.
Methods
Reagents. Predominantly single-chain human rt-PA (lot K9051A6) was obtained from Genentech, Inc., San Francisco, CA. Fragment E was purchased from Diagnostica Stago, Asnieres, France. Plasminogen with an amino-terminal glutamic acid residue (glu-plasminogen) and mouse monoclonal antibody against human t-PA (PAM-2) were purchased from American Diagnostica, New York, NY. A mouse monoclonal antibody against D-dimer (DD), designated 8D3, was generously provided by Dr Preparation of'25I-labeledfibrinogen. Fibrinogen was precipitated from barium sulfate-adsorbed plasma with 2 M ,-alanine as described in detail elsewhere (29). The isolated fibrinogen was then trace labeled with 1251 (30) to a specific activity of 100±5 uCi/mg.
Preparation of'25-labeled cross-linkedfibrin clots. Blood was collected from the antecubital veins of healthy volunteers into plastic syringes prefilled with 1/10 vol of 3.8% trisodium citrate. After thorough mixing with the anticoagulant, the red cells were sedimented by centrifugation at 1,700 g for 15 min at 4°C. The harvested plasma was supplemented with '251I-labeled fibrinogen (-120,000 cpm/ml) and 500-id aliquots were then transferred to polypropylene eppendorf tubes. Labeled cross-linked fibrin clots were formed around wire coils by the addition of CaCl2 (final concentration, 25 mM). For some experiments, '25"-labeled fibrin clots of varying sizes were prepared by the recalcification of plasma in volumes ranging from 250 Ml to 1 ml. In all cases however, the clots were aged for 60 min at 37°C with constant agitation, and then washed three times with l-ml aliquots of 0.1 M NaCI buffered with 0.05 M Tris-HCI, pH 7.4 (TBS) over the course of 30 min. The washed clots were then counted for radioactivity for 1 min using a Clinigamma counter (LKB Instruments, Inc., Gaithersburg, MD).
Clots formed in this fashion are cross-linked because they remain intact after 24 h incubation in 2% acetic acid. Further, SDS-PAGE analysis under reducing conditions of clots solubilized in SDS as described by Francis et al. (31) demonstrates bands corresponding to the f,, gamma-gamma dimers, and a-polymer chains (data not shown). Non-cross-linked a-or gamma-chains are not present, thus indicating virtually complete cross-linking.
Quantification of rt-PA-inducedflbrin(ogen)olysis in the presence or absence of'25I-labeledfibrin clots. rt-PA (at concentrations ranging from 0.125 to 2.0 MLg/ml) was incubated with 500-ul aliquots of fresh citrated plasma for 60 min at 37°C in the presence or absence of'251-labeled fibrin clots, and clot lysis and fibrinogenolysis were then monitored as follows. (a) Clot lysis. The extent of rt-PA-induced clot lysis was quantified (i) by monitoring the time-course of release of '251-labeled fibrin degradation products, and (ii) by removing the fibrin clots from the rt-PA containing plasma, and after washing three times with 500-,d aliquots of TBS, counting the residual radioactivity for 1 min.
The difference between the radioactivity originally incorporated in the clot and the residual radioactivity was then expressed as a percentage of the initial radioactivity. (b) Fibrinogenolysis. The extent of rt-PA-induced fibrinogenolysis was determined by monitoring plasma levels of BO . At intervals, 100--l aliquots of plasma were removed, and unreacted fibrinogen was precipitated by the addition of 300 AL of chilled ethanol followed by centrifugation at 15,000 g for 5 min. The ethanol supernatants were then evaporated to dryness in a Speed-Vac Concentrator (Savant Instruments, Inc., Farmingdale, NY), reconstituted to original volume with distilled water, and assayed for BOB1-42.
In some experiments, immunoblot analysis was used to directly visualize the fibrinogen degradation products. For these studies, 20-Ml aliquots were removed at intervals, diluted in an equal volume of60 mM Tris-HCl containing 2% SDS, 5% glycerol, and 0.00 1% bromophenol blue, heated at 100°C for 5 min, and then stored at -70°C until analyzed as described below.
Radioimmunoassay of B(31-42. The fibrinogen-derived fragment B1Ol-42 was measured by radioimmunoassay as previously described using a specific antibody that does not cross-react with fibrinopeptide B or B,B15-42 (32) .
Preparation of clot lysates. To prepare clot lysates, '251-labeled cross-linked fibrin clots were incubated for 60 min at 37°C in 500-,ul aliquots of TBS containing 4 ug/ml rt-PA and 0.02% Tween 80. At the end of the incubation period, the residual clots were removed, and the clot lysates were then pooled and immunodepleted of rt-PA by affinity chromatography. A mouse monoclonal IgG against the kringle-1 region (33) of human t-PA (PAM-2, American Diagnostica) was coupled to cyanogen bromide activated CH Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ) at a concentration of 20 mg/ml. The clot lysates (10 ml) and anti-t-PA IgG coupled to CH Sepharose 4B (750 M1 ofa 50% suspension) were mixed in a tube and agitated for 1 h at 23°C. After centrifugation at 10,000 g for 5 min, the supernatants were carefully removed, and the immunodepletion procedure was then repeated for two additional 1-h cycles. The final material contained < 50 ng of t-PA as measured antigenically using an enzyme-linked immunosorbent assay kit from American Diagnostica. The lysates were then concentrated 10-fold using an ultrafiltration cell (series 8050, Amicon Division, W. R. Grace & Co., Danvers, MA) fitted with a 5,000-mol wt cut-off membrane (YM5 disc membrane, Amicon), counted for radioactivity for 1 min, and stored in aliquots at -70°C.
The effect of clot lysates on rt-PA-mediated fJbrinogenolysis. To determine whether soluble fibrin degradation products potentiate rt-PA-mediated fibrinogenolysis, varying amounts ofclot lysate or buffer control were incubated in 500-gl aliquots ofcitrated plasma for 60 min at 37°C in the presence or absence of rt-PA (at a concentration of 1 or 2 Ag/ml). At intervals, 100-Ml aliquots were removed, and the unreacted fibrinogen was precipitated with 300 Al of chilled ethanol followed by centrifugation at 15,000 g for 5 min. The ethanol supernatants were then evaporated to dryness, reconstituted to original volume with distilled water, and assayed for B,B1-42.
Adsorption of'25-labeledfibrin degradation products to plasminogen-Sepharose or rt-PA-Sepharose. Glu-plasminogen and rt-PA were each coupled to cyanogen bromide-activated CH Sepharose 4B (Pharmacia Fine Chemicals) at a concentrations of 5 and 1 mg/ml, respectively. Lysates of '25W-labeled fibrin clots were then subjected to affinity chromatography at 23°C on columns (5 x 0.7 cm) containing either glu-plasminogen or rt-PA coupled to CH Sepharose 4B. I-ml fractions were collected and their radioactivity and absorbance at 280 nm were determined. After extensive washing of the columns with TBS, material bound to plasminogen-Sepharose was eluted with TBS containing 0.05 M lysine, whereas that bound to rt-PA-Sepharose was eluted with 0.4 M NaCl buffered to pH 4.0 with 0.1 M ammonium acetate. Again, 1 -ml fractions were collected, and their radioactivity and absorbance at 280 nm were determined. After confirming the protein concentration using the method of Lowry (34) , peak protein-containing fractions were pooled, concentrated using Centricon-10 ultrafiltration cartridges (Amicon Division, W. R. Grace & Co.), and then tested for their ability to potentiate rt-PA-induced fibrinogenolysis in plasma using the method described above.
Gelfiltration ofclot lysates. Crude lysates of '251I-labeled fibrin clots and material eluted from either the plasminogen-Sepharose or the rt-PA-Sepharose columns were subjected to chromatography at 23°C on a column (90 x 1.6 cm) of Sephacryl S-300 HR (Pharmacia Fine Chemicals) using TBS at a rate of 50 ml/h. For preparative procedures, Dextran blue (Sigma Chemical Co., St. Louis, MO) was used to determine the void volume, and the column was calibrated with thyroglobulin, gamma-globulin, ovalbumin, myoglobulin, and cyanocobalamin with molecular weights of 670,000, 158,000, 44,000, 17,000, and 1,350 D, respectively. 2-ml fractions were collected and their radioactivity and absorbance at 280 nm were measured. After confirming the protein concentration using the method of Lowry (34) , peak-protein containing fractions were pooled, concentrated using Centricon-10 ultrafiltration cartridges (Amicon Division, W. R. Grace & Co.), and then tested for their ability to potentiate rt-PA-induced fibrinogenolysis in plasma using the method described above.
PAGE and immunoblot analysis offibrin(ogen) degradation products. Plasma incubated with rt-PA in the presence or absence of fibrin clots, crude clot lysates, the fibrin degradation products that bound and those that did not bind to plasminogen-Sepharose or to rt-PA-Sepharose, and the peak protein-containing fractions recovered from the gel filtration column were characterized using a combination of PAGE and immunoblot analysis. Samples were diluted in an equal volume of 60 mM Tris-HCI containing 0.001% bromphenol blue with or without 2% SDS and 5% glycerol. Two electrophoretic systems were used: a 7.5% polyacrylamide slab gel (4% stacking gel) containing 0.1% SDS using a modified Laemmli discontinuous buffer system (35) under nonreducing conditions and a 7.5% polyacrylamide gel (4% stacking gel) under nondisocciating conditions according to the method of Davis (36) . The gels were either fixed in 40% methanol/10% acetic acid and stained with Coomasie Blue, or the separated proteins were electrophoretically transferred onto nitrocellulose membranes. After blocking in 5% (wt/vol) fat-free milk diluted in 0.15 M NaCl, the membranes were washed and incubated for 90 min with either a 1:3,000 dilution of horseradish peroxidase-conjugated goat anti-human fibrinogen IgG (Cooper Biomedical, Inc.), or a 1:1,000 dilution of rabbit antibody against Fragment E (Diagnostica Stago) or mouse monoclonal IgG against DD (8D3). In the case of the latter two antibodies, the washed membranes were incubated for 60 min with a 1:1,000 dilution ofhorseradish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG (BioRad Laboratories, Inc., Richmond, CA), and all the membranes were then developed with chloronaphthol followed by hydrogen peroxide.
Results
Formation of '25_-labeled fibrin clots. The recalcification of 500-,ul aliquots of plasma containing '251-labeled fibrinogen results in the formation of fibrin clots of standard size. -95% of the radiolabeled fibrinogen is incorporated into the clots so that the radioactivity is 56,943±1,180 cpm (mean±SD).
Increased rt-PA-mediated fibrinogenolysis in the presence offibrin clots. To determine the influence of fibrin on rt-PAmediated fibrinogenolysis, plasma containing increasing concentrations of rt-PA was incubated in the presence or absence of an '25W-labeled cross-linked fibrin clot, and B 13-42 was measured as an index of fibrinogenolysis. As illustrated in Table I , in the absence of fibrin, rt-PA produces concentration-dependent generation of small amounts of Bf31-42 that represent < 1% of the total releasable B31-42 (as calculated from the plasma fibrinogen concentration of 6.2 ,M). In contrast, in the presence of fibrin there is 21-fold increase in the amount of B, 1-42 produced by each concentration ofrt-PA. This increase is not due to the release oftrapped B,B 1-42 from within the clots because < 10 nM B, 1-42 is recovered when clots suspended in buffer are completely lysed by rt-PA (data not shown). That the increase in B,31-42 levels in the presence of a clot reflects enhanced fibrinogen proteolysis is confirmed by the results of immunoblot analysis (Fig. 1) . Marked fibrinogen proteolysis is produced by 1 jig/ml of rt-PA in the presence of a fibrin clot but not in its absence.
Relationship between rt-PA-induced clot lysis andfibrinogenolysis. 1251I-labeled fibrin clots of different sizes were incubated for 60 min at 37°C in plasma containing 1 gg/ml rt-PA, and clot lysis and fibrinogenolysis were quantified. This concentration ofrt-PA was chosen because it represents a therapeutic level (37) . To determine the extent of fibrinogenolysis, the amount of B# 1-42 generated was expressed as a percent of the total releasable B,B1-42 (as calculated from the plasma fibrinogen concentration of 6.2 PM). As illustrated in Fig. 2 , there is a linear relationship between the percent of B,B 1-42 released, and the extent of clot lysis.
To investigate the mechanism for the relationship between clot lysis and fibrinogenolysis, 125I-labeled fibrin clots ofa standard size were incubated for 60 min at 37°C in 500-ll aliquots of plasma containing 1 ug/ml rt-PA. At varying intervals, the clots were removed, and the time-course ofclot lysis was monitored by measuring the release of 1251I-labeled fibrin degradation Clot Lysis (%) Figure 2 . Relationship between the extent of B,B1-42 release and the percentage ofclot lysis. 2'I-labeled fibrin clots of different sizes were incubated in plasma containing I tg/ml of rt-PA for 60 min at 37°C.
At the end of the incubation period, the plasma levels of B,B1-42 were assayed as an index of fibrinogenolysis, whereas the extent of clot lysis was determined by counting the residual radioactivity of the clot. The amount of B,B 1-42 generated was then expressed as a percent ofthe total releasable B, 1-42 which was calculated from the plasma fibrinogen concentration of 6.2 jM. Using linear regression analysis, the correlation coefficient is 0.9987. products (Fig. 3 A) , whereas fibrinogenolysis was followed by measuring the generation of Bj# (Fig. 3 B) . As indicated in Fig. 3 A, the concentration of released 1251-labeled fibrin degradation products depends on the duration of exposure of the clots to rt-PA. Once the clots are removed from the rt-PA containing plasma, release of '25I-labeled fibrin degradation products ceases, whereas fibrinogenolysis continues (Fig. 3 B) primarily mediated by soluble fibrin degradation products because once 25% lysis of the clot has been achieved by a 20-min exposure to rt-PA, the amount of B31-42 generated is almost the same as that produced when clots are incubated with rt-PA for 60 min.
Potentiation of rt-PA-induced fibrinogenolysis by clot lysates. To determine whether soluble fibrin degradation products can potentiate rt-PA-mediated fibrinogenolysis, varying amounts of clot lysate were incubated with rt-PA-containing plasma, and fibrinogenolysis was monitored by measuring the levels of Bp1l-42. As illustrated in Fig. 4 , the addition of clot lysate produces a concentration-dependent increase in the amount of Bo 1-42 that is generated. These studies thus indicate that soluble fibrin degradation products can potentiate rt-PAinduced fibrinogenolysis.
Adsorption of I2SI-labeled fibrin degradation products to plasminogen-Sepharose or rt-PA-Sepharose. To explore the mechanism by which soluble fibrin degradation products potentiate rt-PA-induced fibrinogenolysis, we set out to determine whether these derivatives can bind plasminogen and/or rt-PA by examining the adsorption of these products to plasminogen-Sepharose or rt-PA-Sepharose. -72% of the '251-labeled fibrin degradation products in the crude clot lysates binds to both plasminogen-Sepharose and rt-PA-Sepharose (data not shown). The bound and unbound fractions were analyzed using SDS-PAGE followed by autoradiography (Fig. 5) . Similar fibrin-derived degradation products bind to both plasminogenSepharose and to rt-PA-Sepharose. In each case, two major bands are visualized at -195,000 and 60,000 D, respectively. superatants were as-TIME (miir) sayed for B#31-42. (Table II) . In contrast, the unbound fractions have virtually no potentiating activity. When the crude clot lysates or the fractions that bound to plasminogen-Sepharose or rt-PA-Sepharose were concentrated by lyophylization rather than by ultrafiltration, their potentiating activity was lost, suggesting that the three-dimensional structure of these fragments is an important determinant of their activity.
Gelfiltration offibrin degradation products that bind to plasminogen-Sepharose and to rt-PA-Sepharose. To further characterize the fibrin degradation products that potentiate rt-PA-induced fibrinogenolysis, the crude clot lysates and those fractions of the lysates that bound to plasminogen-Sepharose or to rt-PA-Sepharose were subjected to chromatography on Sephacryl S300 HR to separate the products according to their molecular weights. As illustrated in Fig. 6 , gel filtration of the fractions of clot lysate that bound to plasminogen-Sepharose identified a major protein peak (peak B) which based on its elution profile, has a molecular weight of -255,000 D. In addition, a small high-molecular weight peak (peak A) that eluted in the void volume, and a minor peak (peak C) ofmolecular weight -60,000 D also were identified. Chromatography of the crude lysate and the fractions of the lysate that bound to rt-PA-Sepharose revealed similar peaks (data not shown). The fractions from the gel filtration column were collected, pooled as indicated, concentrated by ultrafiltration, and then characterized by PAGE and immunoblot analysis, and tested for their ability to potentiate rt-PA-induced fibrinogenolysis in plasma.
Characterization offibrin degradation products. The gel filtration fractions were characterized using a combination of PAGE and immunoblot analysis. Electrophoresis was performed under both dissociating (Fig. 7 ) and nondissociating conditions (Fig. 8) . The main protein fraction, peak B (Fig. 6) , was identified as consisting primarily of (DD)E complex because under nondissociating conditions (Fig. 8) there is a single 255,000-D band (Fig. 8 A, lane 3 ) that is recognized both by the antibody against DD (Fig. 8 B, lane 3) and by the antibody against fragment E (Fig. 8 C, lane 3) . In contrast, in the presence of SDS (Fig. 7) this material separates into two bands at -195,000 and 60,000 D, respectively (Fig. 7 A, lane 3) . The higher molecular weight band is recognized by a monoclonal antibody against DD (Fig. 7 B, lane 3) , whereas the lower molecular weight band reacts with an antibody against fragment E (Fig. 7 C, lane 3) . PAGE analysis under dissociating conditions (Fig. 7 A, lane 2) of the peak that elutes in the void volume of the gel filtration column (Fig. 6, peak A) (Fig. 8 B, lane 2) and by an antibody against fragment E (Fig. 8 C, lane 2) . Thus, these species represent high molecular weight derivatives that contain the (DD)E complex.
The lowest molecular weight peak recovered from the gel filtration column (Fig. 6 , peak C) migrates as a major band of -60,000 D under dissociating conditions (Fig. 7 A, lane 4) that is recognized by the antibody against fragment E (Fig. 7 C, lane 4) but not by the antibody against DD (Fig. 7 B, lane 4) . In addition, at least two higher molecular weight bands that are recognized by the antibody against DD also are visualized ( Fig.   7 B, lane 4). These bands are of lower molecular weight than intact DD, and probably represent products of its digestion by plasmin. Under nondissociating conditions, peak C migrates as a minor band at -60,000 D and a major band at -~55,000 D (Fig. 8 A, lane 4) . These bands are recognized by the antibody against fragment E (Fig. 8 C, lane 4) and not by the antibody against DD (Fig. 8 B, lane 4) , indicating that they represent fragment E species.
The fibrin degradation products that do not bind to plasminogen-Sepharose or rt-PA-Sepharose (Fig. 5, lanes 2 bind to plasminogen-Sepharose or to rt-PA-Sepharose (Fig. 5) does not have potentiating activity (Table II) .
Discussion
The activation of plasminogen by t-PA is accelerated in the presence of fibrin (7, 8) . Although fibrinogen has little effect on the rate of t-PA-induced plasminogen activation (7, 8) Methods, and the fractions pooled as indicated in Fig. 6 . The potentiating activity of peaks A, B, and C which represent high-molecular weight derivatives that contain the (DD)E complex, (DD)E complex itself, and fragment E, respectively, was then tested as described above. The values illustrated represent the mean±SD of two different experiments each done in duplicate.
bromide. The physiologic significance of these observations is uncertain however, because many of these fragments are not produced in vivo. In addition, the studies reported to date have only examined the accelerating effect of fibrin(ogen) fragments in buffer systems, and the potential modulating effects of antiproteinases have not been considered. In the present study we have extended the observations made in buffer systems by (a) demonstrating that the physiologic products of rt-PA-induced lysis of cross-linked fibrin can potentiate rt-PA-mediated fibrinogenolysis in a plasma system, (b) identifying and characterizing those fibrin degradation products that have potentiating activity, and (c) demonstrating that the products with potentiating activity bind both plasminogen and rt-PA, which suggests that they act by providing a surface on which the fibrinolytic components can be assembled.
In the presence of fibrin there is an -2 1-fold increase in the amount of B, 1-42 generated by a wide range of rt-PA concentrations (Table I) . That the higher Bf 1-42 concentrations in the presence of fibrin reflect increased fibrinogen proteolysis is confirmed by the results ofimmunoblot analysis which permits direct visualization of the fibrinogen degradation products (Fig. 1) . When clots of increasing size are exposed to the same concentration of rt-PA, there is a linear relationship between the extent of clot lysis and that of fibrinogenolysis (Fig. 2) . This phenomenon cannot be explained on the basis of the larger clots providing a greater surface on which plasmin can be generated because there is ongoing Bfl 1-42 generation after the clots are removed from rt-PA-containing plasma (Fig. 3) . If fibrinogenolysis was mediated by plasmin bound to the clot surface, B,3 production would cease when the clot is removed.
That soluble fibrin degradation products are responsible for the ongoing fibrinogenolysis is suggested by the observation that the extent of BJ3 1-42 generation that occurs after clot removal depends on the time that the clot is exposed to rt-PA, and is established by the demonstration that clot lysates enhance rt-PA-mediated generation of B,#1-42 in a concentration-dependent fashion (Fig. 4) . The potentiating activity of soluble fibrin degradation products involves the binding of rt-PA and plasminogen because only the functionally active products bind both to rt-PA-Sepharose and to plasminogen-Sepharose (Table II) . Further, analysis of the bound products using SDS-PAGE and autoradiography (Fig. 5) indicates that similar derivatives bind to both adsorbants. After separation of these products by gel filtration (Fig. 6) (31, 43) . The other minor peak identified by gel filtration (peak C) has a molecular weight of -60,000 D and represents predominantly fragment E. Analysis under nondissociating conditions indicates that more than one fragment E species is present (Fig. 8 A, (44, 45) .
Whereas high-molecular weight derivatives that contain the (DD)E complex, (DD)E complex itself, and fragment E bind to both plasminogen-Sepharose and rt-PA-Sepharose, DD does not bind (Fig. 5) . These Only the fibrin fragments that have affinity for plasminogen and rt-PA are capable of augmenting fibrinogenolysis (Table II) suggesting that these derivatives act by providing a surface on which the fibrinolytic components can be assembled. Plasmin generated at this site is relatively protected from inactivation by fluid-phase inhibitors because soluble fibrin degradation products potentiate rt-PA-induced B,31-42 generation in plasma (Fig. 4) . Other investigators have demonstrated that high-molecular weight derivatives of cross-linked fibrin (27) and (DD)E complex (28) can accelerate rt-PA-induced activation ofplasminogen in a buffer system. We have extended these observations in three ways. First, we have shown that in addition to these derivatives, fragment E also potentiates rt-PA-induced fibrinogenolysis (Table III) . Quantitatively, however, (DD)E complex, the major product of plasmin degradation of cross-linked fibrin, is the most potent stimulator of fibrinogenolysis (Table III) . Second, because our studies were done in a plasma system, they indicate that plasmin generated on the surface of fibrin degradation products is relatively protected from inactivation by fluid-phase antiplasmins. Third, the data presented in Fig. 3 suggest that plasmin generated on the surface of fibrin degradation products is a more important mediator of fibrinogenolysis than plasmin generated on the clot surface.
In summary, we have demonstrated that the products of rt-PA-induced degradation of cross-linked fibrin can potentiate rt-PA-mediated fibrinogenolysis by providing a surface for t-PA and plasminogen binding thereby promoting plasmin generation. The occurrence ofthis phenomenon after therapeutic thrombolysis may explain the limited fibrin selectivity of rt-PA.
